Related Experiment Videos
Treatment of experimental cryptococcal meningitis and disseminated candidiasis with SCH39304
J R Perfect1, K A Wright, M M Hobbs
1Department of Medicine, Duke University Medical Center, Durham, North Carolina 27710.
Abstract:
We studied the pharmacokinetics and in vivo antifungal action of SCH39304, a new antifungal azole compound, in rabbits. It crossed the blood-cerebrospinal fluid barrier in the presence or absence of meningeal inflammation, reaching approximately 60% of the simultaneous concentrations in serum. In the treatment of experimental cryptococcal meningitis, SCH39304 was as effective as fluconazole in reducing yeast counts in the subarachnoid space. SCH39304 and fluconazole both were highly effective against candida endophthalmitis, sterilizing the vitreous humor and the choroid and retina. SCH39304 suppressed candida endocarditis and reduced yeast counts in the kidney at all doses tested. SCH39304 was effective in the treatment of experimental cryptococcal meningitis and disseminated candidiasis. Further investigations in humans are warranted.
Insights
New antifungal azole SCH39304 demonstrates potent in vivo antifungal activity against cryptococcal meningitis and candidiasis in rabbits. Further human studies are recommended for this promising compound.
Area of Science:
- Pharmacology
- Mycology
- Infectious Diseases
Background:
- Azole compounds are crucial in antifungal therapy.
- SCH39304 is a novel azole with potential therapeutic applications.
- Understanding its pharmacokinetic and pharmacodynamic properties is essential.
Purpose of the Study:
- To evaluate the pharmacokinetics of SCH39304 in rabbits.
- To assess the in vivo antifungal efficacy of SCH39304 against experimental fungal infections.
- To compare SCH39304 with fluconazole in treating specific fungal infections.
Main Methods:
- Pharmacokinetic studies in rabbits, including penetration of the blood-cerebrospinal fluid barrier.
- In vivo efficacy studies using rabbit models of cryptococcal meningitis, candida endophthalmitis, and disseminated candidiasis.
- Yeast counts were determined in relevant tissues and bodily fluids.
Main Results:
- SCH39304 effectively penetrated the blood-cerebrospinal fluid barrier.
- In cryptococcal meningitis models, SCH39304 showed efficacy comparable to fluconazole.
- SCH39304 demonstrated high efficacy against candida endophthalmitis and suppressed candida endocarditis and disseminated candidiasis.
Conclusions:
- SCH39304 exhibits favorable pharmacokinetics and potent in vivo antifungal activity.
- The compound is effective in treating experimental cryptococcal meningitis and candidiasis.
- Further clinical investigations in humans are warranted to establish its therapeutic potential.